Imagine two people with the same stage of colon cancer. They get the same surgery and the same chemotherapy plan. One thrives for years. The other sees their cancer return quickly.
Why?
This frustrating reality is at the heart of a new medical commentary. It asks a tough question: Are we doing enough, even when we follow all the rules?
Colorectal cancer is the third most common cancer in the United States. For non-metastatic disease—meaning it hasn’t spread far—treatment usually involves surgery and often chemotherapy.
Doctors rely on detailed guidelines to choose that chemo. These rules are based on the cancer’s stage, seen under a microscope.
This system has saved countless lives. But it has a blind spot.
It treats many unique cancers as if they are the same.
The Cookie-Cutter Problem
The current approach is like giving the same key to everyone, hoping it fits their lock. Sometimes it works perfectly. Other times, the key doesn’t turn.
The tumor’s genetics provide some clues. But even that isn't the full picture.
Here’s the twist: a tumor isn’t a uniform mass. It can contain different groups of cells that behave in wildly different ways. One drug might kill one group but miss another.
This hidden diversity can lead to treatment resistance, recurrence, and unnecessary side effects from drugs that don't work.
A More Personal Blueprint
So, what’s the new idea? It’s called functional precision medicine.
Think of it as a "trial run" for chemotherapy. After surgery, a sample of the patient’s living tumor cells is tested in a lab with different drugs. Scientists watch to see which therapies actually kill the cancer cells.
It’s a direct measure of what works for that patient’s unique biology.
This approach doesn't replace guidelines or genetic tests. It complements them. It adds a real-world, functional layer of information.
The authors of this paper, published in Frontiers in Medicine, looked back at past colorectal cancer cases. They correlated these live-cell drug test results with how patients actually fared.
They found a link between the test results and patient outcomes. This suggests the tests have real predictive power.
More intriguingly, they showed these tests could spot that hidden diversity within a single patient's tumor. They identified sub-groups of cells with different drug sensitivities.
This is critical. It means a single drug might leave a dangerous group of cells behind.
But There’s a Catch.
This doesn’t mean this treatment is available yet.
The evidence is promising but still retrospective—looking back at old data. What’s needed are large, forward-looking clinical trials. These trials would randomly assign patients to get treatment based on the standard guideline or the functional test.
Only then will we know for sure if it leads to better survival.
The researchers are clear. Guideline-concordant care is necessary and saves lives. But for many patients, it may not be sufficient.
The goal is to build a more personalized framework. One that uses every tool—pathology, genetics, and functional testing—to build the best possible plan for the individual in front of you.
If you or a loved one is facing colorectal cancer treatment, this is a developing area of science. The functional tests discussed are not standard of care and are not widely available.
Your best action is to have a detailed conversation with your oncology team. Ask them: “Based on my specific stage and pathology, what are all my options?” and “How are we personalizing my treatment plan?”
Always follow the guidance of your treating physicians.
The Limitations
This is an early-stage hypothesis supported by correlative data. The studies so far are small and retrospective. We do not yet have proof that using these tests to guide therapy improves long-term survival rates.
The path forward requires rigorous clinical trials. These trials are complex, expensive, and take years to complete. Researchers need to prove that this personalized approach is not just interesting, but truly better, before it can become a new standard.
The journey is just beginning. But the destination is a future where cancer treatment is tailored as uniquely as your fingerprint.
5. ENDING
If this kind of personalized testing became available, is it something you would want to explore with your care team?
6. SEO BOOST (Internal Linking)
Questions to ask your oncologist at your first appointment Understanding the stages of colorectal cancer What is precision medicine in cancer treatment?
